Download presentation
Presentation is loading. Please wait.
Published byΣουσάννα Καρράς Modified over 6 years ago
1
History of the Development of Antiemetic Guidelines at Mayo Clinic Rochester
Charles L. Loprinzi, MD, Steven R. Alberts, MD, Bradley J. Christensen, BS Pharm, Lorelei J. Hanson, RN, David R. Farley, MD, Joan K. Broers, RN, Donna L. Betcher, RN, Robert E. Grady, MD, Peter A. Southorn, MD, Todd M. Johnson, PharmD, Edith A. Perez, MD Mayo Clinic Proceedings Volume 75, Issue 3, Pages (March 2000) DOI: / Copyright © 2000 Mayo Foundation for Medical Education and Research Terms and Conditions
2
Figure 1 Mean episodes of emesis per person per day for patients receiving grade 3 emetogenic chemotherapy (left) or grade 4 emetogenic chemotherapy (right). Patients with 5 or more episodes of emesis per day were classified as having 5 emesis episodes for that day. Mayo Clinic Proceedings , DOI: ( / ) Copyright © 2000 Mayo Foundation for Medical Education and Research Terms and Conditions
3
Figure 2 Percentage of patients with complete emesis control (no emetogenic episodes) per day for those receiving grade 3 emetogenic chemotherapy (left) or grade 4 emetogenic chemotherapy (right). Mayo Clinic Proceedings , DOI: ( / ) Copyright © 2000 Mayo Foundation for Medical Education and Research Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.